The SGX945 proof of concept pilot study was an open-label study that enrolled 8 patients age 18 years or older with mild to ...

EAST HANOVER, NJ, USA I July 31, 2025 I Novartis announced today that the US Food and Drug Administration (FDA) has approved a label update for Leqvio® ...

TAIPEI, Taiwan I August 1, 2025 I Energenesis Biomedical Co., Ltd. (TWSE: 6657), a clinical-stage biotechnology company focused on cellular energy restoration ...

EMERYVILLE, CA, USA I July 31, 2025 I 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing ...

LOS ANGELES, CA, USA I July 30, 2025 I Trethera Corporation (“Trethera”), a clinical stage biopharmaceutical company ...

Findings from the TRAILBLAZER-ALZ 2 long-term extension study highlight Kisunla continued to demonstrate slowing of decline, with most participants having ...

(“Be Bio” or “the Company”), a clinical-stage company pioneering the discovery and development of engineered B Cell Medicines (BCMs), today announced the first participant was treated with BE-101 in ...

CAMBRIDGE, MA, USA I July 30, 2025 I Moderna, Inc. (NASDAQ:MRNA) today announced that the European Commission (EC) has granted marketing authorization for the ...

Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer's Disease ...

NORTH CHICAGO, IL, USA I July 30, 2025 I AbbVie (NYSE: ABBV) today announced positive topline results from the first of two pivotal studies of the Phase 3 ...

Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening ...

SAN DIEGO, CA, USA I July 30, 2025 I EuMentis Therapeutics, Inc., (“EuMentis”), a clinical-stage drug development company focused on advancing novel treatments for schizophrenia and other central ...